Envision Report

Published January 11, 2018

South America Diabetes Drugs Market – Size, Outlook, Trends and Forecasts (2018 – 2024)

Request Free Sample Report!

Doctors often refer diabetes as diabetes mellitus, describes a group of metabolic diseases in which the person has high blood glucose (blood sugar), either because insulin production is inadequate, or because the body’s cells do not respond appropriately to insulin or both. Patients with high blood sugar typically experience polyuria (frequent urination), and become increasingly thirsty (polydipsia) and hungry (polyphagia).

South America Diabetes Drugs Market  Segments Size & Growth:

South America diabetes drugs market size is projected to reach approximately $28 billion by the end of 2024 with a CAGR of close to 6.6% from $20 billion in 2017 during the forecast timeline 2018-2024. Key parameters promoting the market growth include Rise in some diabetics, Government Initiatives and Complexities in alternative diabetes therapy. However, Cost sensitivity issues, Lack of awareness among people and Regulatory framework issues are thereby hampering the market growth.

South America Diabetes Drugs Market  Segments Share:

South America diabetes drugs market is categorised into Drugs which comprise of Insulin Derivatives and Oral Diabetic Medication Drugs. By Drugs, Oral Diabetic Medication Drugs segment is expected to hold the most significant share in the market. By Geography, Brazil is projected to dominate the market with the most significant share and the growth in the South America economies is mainly attributed because of huge profit margins and growth prospects.

South America Diabetes Drugs Market  Trends:

  • Novo Nordisk is working on Degludec and DegludecPlus as acceptable long-acting choices. It is longer acting and improves blood glucose levels with a lower risk of hypoglycemia, especially during the nighttime. It will be more accessible and more flexible with dosing, possibly three times weekly. Degludec will also have a U-200 version, which allows more insulin in a reduced volume for those who require large amounts. DegludecPlus has a fixed dose of mealtime (30% Novolog) and basal (70% Degludec) insulin. Novo-Nordisk was filing for FDA approval for this new insulin in January 2012.
  • Echo Therapeutics – The Symphony System. It is a non-needle, non-invasive, wireless trans-dermal continuous glucose monitoring system. The Symphony System uses a biosensor without the need to prick the skin since it is trans-dermal (it is an adhesive patch placed on the surface). FDA has approved it and is showing substantial successes in clinical trials. Testing is being done on hospitalised critical care patients who require multiple finger sticks daily.

South America Diabetes Drugs Market  Research Report:

  • An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
  • To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.
  • Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year
  • Identifying DROC in the current market and their impact in altering the market dynamics.
  • Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial study with significant competitors.
  • Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
  • The primary market players, such as
  • Novo Nordisk
  • Eli Lilly and Company
  • Sanofi Aventis
  • Takeda Pharmaceuticals
  • Oramed Pharmaceuticals

1. Introduction

1.1 Executive Summary

1.2 Market Definition

1.3 Scope of the Study

2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.3 Analytic Tools and Model

2.4 Economic Indicator

2.4.1 Base Year, Base Currency, Forecasting Period

2.5 Expert Validation

2.6 Study Timeline

3. Market Analysis

3.1 Industry Value Chain Analysis

3.2 Porter’s Five Analysis

3.2.1 Bargaining Power of Buyers

3.2.2 Bargaining Power of Suppliers

3.2.3 Threats of Substitutes

3.2.4 Threats of New Entrants

3.2.5 Industry Rivalry

3.3 PESTLE Analysis

3.3.1 Political

3.3.2 Economical

3.3.3 Social

3.3.4 Technological

3.3.5 Legal

3.3.6 Environmental

3.4 SWOT Analysis

3.4.1 Strengths

3.4.2 Weakness

3.4.3 Opportunities

3.4.4 Threats

3.5 Y-O-Y Analyses

4. Market Dynamics

4.1   Drivers

4.1.1 Strong encouragement from the governments

4.1.2 Complexities in alternative diabetic therapies

4.1.3 Rise in the number of diabetics

4.2   Restraints

4.2.1 Cost sensitivity issues

4.2.2 Lack of awareness among people

4.2.3 Regulatory framework issues

4.3   Opportunities

4.3.1 approvals of new drugs such as Canagliflozin and dapagliflozin

4.4   Challenges

4.4.1 Cost sensitivity

4.4.2 Low awareness

4.4.3 Regulatory Framework

4.4.4 Effective Disease Management

5. South America Diabetes Drugs Market By Drugs

5.1 Insulin Derivatives

5.1.1 Rapid-acting insulin

5.1.2 Intermediate-acting insulin

5.1.3 Long-acting insulin

5.2 Oral Diabetic Medication Drugs

5.2.1 Sulfonylurea

5.2.2 Metformin

5.2.3 Alpha-Glucosidase inhibitor

5.2.4 Thiazolidinediones

5.2.5 Biguanide

5.2.6 Meglitinides

5.2.7 GPP4-Inhibitors

6. South America Diabetes Drugs Market By Country

6.1.Introduction

6.2.Brazil

6.3.Argentina

6.4. Chile

6.5 Rest of South America

7. Company Profiles

7.1 EMS Farma

7.2 Probiomed

7.3 Sinergium Biotech

7.4 Biosidus

7.5 Amega Biotech

7.6 Sandoz

7.7 Gan & Lee Pharmaceutical

7.8 Xinbai Pharmaceutical

7.9 Wanbang Biopharma

7.10 Halozyme Therapeutics

7.11 Oramed Pharmaceuticals Inc.

7.12 Merck KGaA

7.13 Dongbao Enterprise Group Co., Ltd.

7.14 Biocon

7.15 Boehringer Ingelheim

8. South America Diabetes Drugs Market Competitive Landscape

8.1 Market Share Analysis

8.2 Strategies Adopted by top companies

8.3 Mergers, Acquisitions, Collaborations  & Agreements

9. Market Insights

9.1 Insights of Industry Experts

9.2 Investment  Opportunities

9.3 Analyst Opinion

  1. Appendix

10.1 List of Tables

10.2 List of Figures

  • Competitive Analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors.
  • Monitoring the external and internal factors which affect the market dynamics with the aid of PESTLE analysis.
  • The Regional and Global Variety is taken care of in the report.
  • Year on Year basis generation of revenue is studied.
  • Porter's Five Forces analyze the intensity of competition in an industry and its profitability level.
  • The overview and the sustainability of the market are analyzed through SWOT.
  • DROC is recognized in the current market scenario and see how its effect on market dynamics.
  • The segment-level analysis in terms of type and technology.
  • The value chain analysis, value that's created and captured by a company is the profit margin.Value
  • Created and Captured – Cost of Creating that Value = Margin
  • An executive summary consists of the whole report and the outcome is been given in the report to have brief knowledge about the report.
  • Basis on the depth of the study we approach using analytical tools
  • Expertise investment opportunities are given after analyzing the market to give the organization and the individual to have perfect knowledge about the market.

 

©2018 - Envision Inteligence | All Rights Reserved.